FDA: Wyeth's DTC for ReFacto has unsubstantiated safety claims

Share this article:
A Wyeth Pharmaceuticals direct-to-consumer brochure for ReFacto antihemophilic factor contains unsubstantiated safety claims, according to an FDA notice of violation letter. The brochure, titled “Bob's World,” contained a “Pathogen Safety” sub-section claiming state-of-the-art manufacturing techniques to optimize pathogen safety.
Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...